US Puts Price Tag On False COVID-19 Claims
First Amendment No License For Health Care Providers To Make False Claims
Executive Summary
Until coronavirus public health emergency ends, FTC is authorized to order civil penalties of $43,792 per violation found in COVID-19-related advertising. Health care providers, meanwhile, advertising to treat COVID-19 might be unfamiliar with
You may also be interested in...
In Rare Cannabinoids, BioMedican Sees Alphabet Of Potential Dietary And Drug Ingredients
BioMedican is ready to produce CBG, cannabigerol, and THC-V, tetrahydrocannabivarin, through biosynthesis and plans by the end of the year to start making CBN, cannabinol, and THC-A, tetrahydrocannabinolic-acid.
‘Pharmaceutical’ Controls, Lower Costs: Future Of Cannabinoid Ingredients In Biosynthesis?
Synthetics are necessary for drugs containing cannabinoids because the active ingredient must be consistent from dose to dose. Cannabinoids extracted from hemp vary from plant to plant and more widely from crop to crop, but consistency should matter for cannabinoids used as dietary ingredients, says BioMedican president Dennis O’Neill.
US FDA’s 30-Day Extension For Nitrosamine Assessments Short Of Industry Recommendation
Revision to FDA's September 2020 guidance on assessing nitrosamine impurity risks associated with all chemically synthesized APIs and all approved drug products that contain those APIs doesn’t satisfy industry stakeholders.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: